Search Results - Isabelle Madelaine

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Randomised controlled trial to assess the impact of hospital–community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral anticancer drugs—a French Society for Oncology Pharmacy (SFPO) study: DROP-SFPO study protocol

    Randomised controlled trial to assess the impact of hospital–community pharmaceutical care on drug-related problems in oncology practice for at-risk outpatients treated with oral a... by Patrick Tilleul, Christophe Bardin, Bertrand Pourroy, Florence Ranchon, Catherine Rioufol, Laure Huot, Isabelle Madelaine, Jean Louis Cazin, François Lemare

    Published 2025-06-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

    Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau

    Published 2025-07-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: